» Articles » PMID: 24351660

Feasibility of Endoscopic Assessment and Treating to Target to Achieve Mucosal Healing in Ulcerative Colitis

Overview
Specialty Gastroenterology
Date 2013 Dec 20
PMID 24351660
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Mucosal healing (MH) as a treatment target for ulcerative colitis is of growing interest because it is associated with improved clinical outcomes. However, the feasibility and probability of reaching MH in clinical practice is unknown. We therefore evaluated the feasibility of "treating to target" according to endoscopic findings to reach MH.

Methods: All endoscopic outcomes of patients with ulcerative colitis followed in a single inflammatory bowel disease unit from 2011 to 2012 were reviewed and subsequent therapeutic management. Cumulative incidence of MH and histologic healing (HH) were estimated using a Kaplan-Meier method.

Results: A total of 60 patients underwent at least 2 consecutive endoscopic assessments, of whom 45 and 48 patients had endoscopic and histologic evidence of active disease, respectively. After a median follow-up of 76 weeks, 27 of 45 (60%) patients with endoscopic disease activity at baseline achieved MH and 24 (50%) of 48 patients with histologic disease activity at baseline had HH. The cumulative probabilities of MH were 26%, 52%, and 70% at 26, 52, and 76 weeks, respectively. The cumulative probabilities of HH at weeks 26, 52, and 76 from the time of initial procedure were 19%, 41%, and 57%, respectively. Any adjustment in medical therapy in case of persistent endoscopic activity was associated with both MH and HH.

Conclusions: Repeated assessment of endoscopic disease activity with adjustment of medical therapy to the target of MH is feasible in clinical practice in patients with ulcerative colitis, and seems to be of benefit.

Citing Articles

Limited validity of Mayo endoscopic subscore in ulcerative colitis with concomitant primary sclerosing cholangitis.

Wohl P, Krausova A, Wohl P, Fabian O, Bajer L, Brezina J World J Gastrointest Endosc. 2024; 16(11):607-616.

PMID: 39600557 PMC: 11586720. DOI: 10.4253/wjge.v16.i11.607.


Benefits and Challenges of Treat-to-Target in Inflammatory Bowel Disease.

West J, Tan K, Devi J, Macrae F, Christensen B, Segal J J Clin Med. 2023; 12(19).

PMID: 37834936 PMC: 10573216. DOI: 10.3390/jcm12196292.


Shooting for the Stars: Review of the STARDUST Trial and the Treat-to-Target Approach for Crohn's Disease.

Shawn G, Hou J Gastroenterol Hepatol (N Y). 2022; 18(5):243-247.

PMID: 36397755 PMC: 9666819.


Endoscopic activity in inflammatory bowel disease: clinical significance and application in practice.

Kim K Clin Endosc. 2022; 55(4):480-488.

PMID: 35898147 PMC: 9329646. DOI: 10.5946/ce.2022.108.


Systematic review and meta-analysis: the advantage of endoscopic Mayo score 0 over 1 in patients with ulcerative colitis.

Viscido A, Valvano M, Stefanelli G, Capannolo A, Castellini C, Onori E BMC Gastroenterol. 2022; 22(1):92.

PMID: 35240984 PMC: 8895505. DOI: 10.1186/s12876-022-02157-5.